Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol

Drug Safety

Volumn 35, Issue 7, 2012, Pages 547-553

  Muzyk, Andrew J ^a,b   Rayfield, Amber ^a   Revollo, Jane Y ^c   Heinz, Heather ^c   Gagliardi, Jane P ^b  

^a CAMPBELL UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Antipsychotics; ECG; Haloperidol; Intravenous; QT interval prolongation; Risk factors; Torsades de pointes

Indexed keywords

HALOPERIDOL; MAGNESIUM; POTASSIUM;

ACUTE PSYCHOSIS; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; DELIRIUM; DRUG MONITORING; DRUG SAFETY; DRUG USE; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SUDDEN DEATH; TORSADE DES POINTES;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DEATH, SUDDEN, CARDIAC; FEMALE; HALOPERIDOL; HOSPITALIZATION; HUMANS; INJECTIONS, INTRAVENOUS; LONG QT SYNDROME; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TORSADES DE POINTES;

EID: 84862583397     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11599960-000000000-00000     Document Type: Article

References (35)

1. Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill. Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists (ASHP), American College of Chest Physicians. Crit Care Med 2002; 30: 119-41
2. American Psychiatric Association. Practice guidelines for the treatment of patients with delirium. Am J Psychiatry 1999; 156 Suppl. 5: 1-20
3. Campbell N, Boustani MA, Ayub A, et al. Pharmacological management of delirium in hospitalized adults: a systematic evidence review. J Gen Intern Med 2009; 24: 848-53
4. Lacasse H, Perreault MM, Williamson DR. Systematic review of antipsychotics for the treatment of hospitalacquired delirium in medically or surgically ill patients. Ann Pharmacother 2006; 40: 1966-73 (Pubitemid 44747466)
5. Rea RS, Battistone S, Fong JJ, et al. Atypical antipsychotics versus haloperidol for treatment of delirium in acutely ill patients. Pharmacotherapy 2007; 27: 588-94 (Pubitemid 46536239)
6. Seitz DP, Gill SS, van Zyl LT. Antipsychotics in the treatment of delirium: a systematic review. J Clin Psychiatry 2007; 68: 11-21 (Pubitemid 46220119)
7. Lonergan E, Britton AM, Luxenberg J. Antipsychotics for delirium. Cochrane Database Syst Rev 2009; (2): CD005594
8. Schwartz TL,Masand PS. The role of atypical antipsychotics in the treatment of delirium. Psychosomatics 2002; 43: 171-4
9. Fricchione GL, Nejad SH, Esses JA, et al. Postoperative delirium. Am J Psychiatry 2008; 165: 803-12 (Pubitemid 351948711)
10. US FDA. Information for healthcare professionals: haloperidol (marketed as Haldol, Haldol Decanoate and Haldol Lactate). 2007 (this alert highlights revisions to labeling for haloperidol) [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/DrugSafetyInformation forHeathcareProfessionals/ucm085203.htm : www.fda.gov [Accessed 2011 Sep]
11. Wilt JL, Minnema AM, Johnson RF, et al. Torsade de pointes associated with the use of intravenous haloperidol. Ann Intern Med 1993; 119: 391-4 (Pubitemid 23310089)
12. Perrault LP, Denault AY, Carrier M, et al. Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting. Can J Anesth 2000; 47: 251-4
13. Hunt N, Stern TA. The association between intravenous haloperidol and torsades de pointes. Psychosomatics 1995; 36: 541-9
14. O'Brien JM, Rockwood RP, Suh KI. Haloperidol-induced torsade de pointes. Ann Pharmacother 1999; 33: 1046-50 (Pubitemid 29489985)
15. Kriwisky M, Perry GY, Tarchitsky D, et al. Haloperidolinduced torsades de pointes. Chest 1990; 98: 482-4
16. Metzger E, Friedman R. Prolongation of the corrected QT and torsade de pointes cardia arrhythmia associated with intravenous haloperidol in the medically ill. J Clin Psychopharmacol 1993; 13: 128-32 (Pubitemid 23087229)
17. Sharma ND, Rosman HS, Padhi D, et al. Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998; 81: 238-40 (Pubitemid 28057213)
18. Hatta K, Takahashi T, Nakamura H, et al. The association between intravenous haloperidol and prolonged QT interval. J Clin Psychopharm 2001; 21: 257-61 (Pubitemid 32452929)
19. Tisdale JE, Padhi ID, Sharma ND, et al. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of torsades de pointes. J Clin Pharmacol 2001; 41: 1310-8 (Pubitemid 33104898)
20. Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med 2010; 5: E8-16
21. Haloperidol [package insert]. Princeton (NJ): Sandoz Inc, 2008 Sep
22. Titier K, Girodet PO, Verdoux H, et al. Atypical antipsychotics: from potassium channels to torsade pointes and sudden death. Drug Saf 2005; 28: 35-51
23. Glassman AH. Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry 2005; 66 Suppl. 6: 5-10 (Pubitemid 41243256)
24. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002; 62: 1649-71 (Pubitemid 34848372)
25. Justo D, Prokhorov V, Heller K, et al. Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors. Acta Psychiatr Scand 2005; 111: 171-6 (Pubitemid 40342184)
26. Vieweg WV, Wood MA, Fernandex A, et al. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 2009; 26: 997-1012
27. Bazett JC. An analysis of the time-relations of electrocardiograms. Heart 1920; 7: 353-70
28. Al-Khatib SM, Allan LaPointe NM, Kramer JM, et al. What clinicians should know about the QT interval. JAMA 2003; 289: 2120-7 (Pubitemid 37430214)
29. Vieweg WV. New generation antipsychotic drugs and QTc interval prolongation. Prim Care Companion J Clin Psych 2003; 5: 205-15
30. Arizona Cert-Center for Education and Research on Therapeutics [online]. Available from URL: http://www. azcert.org/[Accessed 2011 Aug 1]
31. Devlin JW, Bhat S, Roberts RJ, et al. Current perceptions and practices surrounding the recognition and treatment of delirium in the intensive care unit: a survey of 250 critical care pharmacists from eight states. Ann Pharmacother 2011; 45: 1217-29
32. Desai M, Li L, Desta Z, et al. Variability of heart rate correction methods for the QT interval. Br J Clin Pharmacol 2002; 55: 511-7
33. Blom MT, Bardai A, van Munster BC, et al. Differential changes in QTc duration during in-hospital haloperidol use. PLoS ONE 2011; 6: e23728
34. Hatta K, Takahashi T, Nakamura H, et al. Hypokalemia and agitation in acute psychotic patients. Psychiatry Res 1999; 86: 85-8 (Pubitemid 29234432)
35. Trojak B, Astruc K, Pinoit JM, et al. Hypokalemia is associated with lengthening of the QT interval in psychiatric patients on admission. Psychiatry Res 2009; 169: 257-60